Summary
This 8-K filing from Bristol-Myers Squibb (BMY) on March 9, 2007, primarily reports on changes to the company's Board of Directors and its bylaws. The key event is the election of Michael Grobstein to the Board of Directors, effective March 6, 2007. His appointment also included a position on the Audit Committee, and the Board size was expanded to eleven members to accommodate this addition. The filing also details an amendment to the company's bylaws, made on March 7, 2007. This amendment removed the reference to an Executive Committee of the Board and specifically established the Compensation and Management Development Committee and the Committee on Directors and Corporate Governance. These changes indicate adjustments in the company's governance structure.
Key Highlights
- 1Michael Grobstein elected to the Board of Directors, effective March 6, 2007.
- 2Michael Grobstein appointed to the Audit Committee of the Board of Directors.
- 3The size of the Board of Directors was increased to eleven members.
- 4Bylaws amended on March 7, 2007, to remove reference to an Executive Committee.
- 5Bylaws amended to specifically provide for the Compensation and Management Development Committee and the Committee on Directors and Corporate Governance.
- 6The changes reflect adjustments to the company's corporate governance framework.